





Levi et al. (1) report elevated stan-
dardized incidence ratios (SIRs) for
nonmelanomatous skin cancer (NMSC)
in women listed with cervical and vul-
var/vaginal cancers in the Vaud cancer
registry, Vaud, Switzerland. This find-
ing is interpreted as support for a role of
human papillomaviruses (HPVs) in the
etiology of NMSC. We feel prompted to
comment on this interpretation and to
present additional observations that may
help clarify the topic.
We identified all women reported to
the national cancer registry in Denmark
with invasive cervical, vulvar/vaginal,
and anal cancers during the period from
1943 through 1990 and all women with
cervical intraepithelial neoplasia (grade
III) or carcinoma in situ during the pe-
riod from 1958 through 1990. Women
with colorectal, breast, and uterine cor-
pus cancers (all HPV unassociated) dur-
ing the period from 1943 through 1990
were also identified. We followed all
women for new cancers and calculated
SIRs and 95% confidence intervals
based on the Poisson distribution as de-
scribed previously (2).
SIRs for cancer overall were signifi-
cantly elevated in all anogenital cancer
cohorts (SIR 4 1.13–1.49), and SIRs
for NMSC were also consistently el-
evated (SIR 4 1.20–1.81). Women with
HPV-unassociated cancers also had el-
evated SIRs for NMSC (SIR 4 1.14–
1.35) (Table 1).
The number of expected cancers, and
thus the size of the SIR, depend on the
completeness of cancer registration in
the population at large. Levi et al. (3)
previously considered underregistration
of NMSCs to be substantial, but they did
not discuss this important point in their
recent letter (1). What their SIR esti-
mates tell is that women registered with
cervical and vulvar/vaginal malignan-
cies in Vaud, Switzerland, are statisti-
cally more likely also to have a subse-
quent registered NMSC than other
women in that population. We found
similar statistical associations for
women with anogenital cancers in Den-
mark but elevated SIRs for NMSC were
not a specific finding. Patients with ano-
genital cancer had significantly in-
creased SIRs for cancer in general, a
context hardly justifying speculations
about the possible etiologic involvement
of (anogenital types of) HPV in NMSCs.
Moreover, patients with HPV-unassoci-
ated cancers also had elevated SIRs for
NMSC, which renders the proposed role
of HPV in NMSC even less appealing.
Important common characteristics for
all the women studied may be the close
clinical follow-up and an increased in-
dividual alertness toward new symp-
toms. Recalling the problem of under-
registration, patients whose NMSCs
actually end up in cancer registries may
well be those who, for a variety of rea-
sons, have close contact to the health
care system.
The finding that patients with NMSC
are not at any increased subsequent cer-
vical cancer risk (4,5) was recently con-
firmed by Levi et al. (6). This lack of an
association further detracts from the
idea that anogenital HPV types are in-
volved in NMSCs. Inference of biologic
significance from epidemiologic asso-
ciations should not rest on statistical sig-
nificance alone. Repeated, unsuccessful
attempts to explain a new association by
potential limitations in the data should
precede etiologic speculations. Such
considerations often favor alternative,
Table 1. Observed and expected cases and standardized incidence ratios (SIRs) of subsequent cancers (overall) and nonmelanomatous
skin cancers among women with anogenital cancers, colorectal cancer, breast cancer, and cancer of the uterine corpus in Denmark during
the period from 1943 through 1990*



















Cervix, preinvasive§ 30 294 374 640 2212 1801.9 1.23 (1.18–1.28) 263 190.0 1.38 (1.22–1.56)
Cervix, invasive 32 307 360 290 3399 3020.0 1.13 (1.09–1.16) 362 295.8 1.22 (1.10–1.36)
Vulva/vagina 3840 23 956 360 297.0 1.21 (1.09–1.34) 60 33.2 1.81 (1.38–2.33)
Anus 684 3724 65 43.6 1.49 (1.15–1.90) 6 5.0 1.20 (0.44–2.61)
HPV‡-unassociated cancers
Colon/rectum 54 635 197 300 2800 2665.5 1.05 (1.01–1.09) 371 308.0 1.20 (1.08–1.33)
Breast 85 243 589 484 6122 6384.2 0.96 (0.94–0.98) 929 688.8 1.35 (1.26–1.44)
Uterine corpus 19 254 178 442 2172 2147.9 1.01 (0.97–1.05) 267 234.4 1.14 (1.01–1.28)
*Inclusion period restricted to the period from 1958 through 1990 for women with preinvasive cervical cancer.
†CI 4 confidence interval.
‡HPV 4 human papillomavirus.
§Women diagnosed with cervical carcinoma in situ or cervical intraepithelial neoplasia (grade III) are included.
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usually less spectacular, explanations of
new findings. Other HPV types may be
involved, but current epidemiologic and
molecular biologic evidence still does
not suggest the involvement of anogeni-
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RESPONSE
Frisch and Hjalgrim suggest that in-
creased diagnosis of nonmelanomatous
skin cancer may, partly or totally, ex-
plain the excess incidence observed af-
ter diagnosis of cervical, vaginal, or vul-
var neoplasms in the Vaud cancer
registry dataset (1).
Such a differential diagnostic atten-
tion is a function of the completeness of
registration of nonmelanomatous skin
cancer. This completeness is uniquely
high in the Vaud population, which has
long been particularly well surveyed
with reference to skin neoplasms. In this
area, in fact, surgically resected cutane-
ous lesions have traditionally been ex-
amined pathologically, and incidence
data of nonmelanomatous skin cancers
from this registry have been used as ref-
erence estimates over the last two de-
cades (2–4). Thus, registered incidence
of nonmelanomatous skin cancers dur-
ing the period from 1988 through 1992
was appreciably higher in Vaud (100
cancers per 100 000 males and 76 can-
cers per 100 000 females; world stan-
dard) than in Denmark (53 cancers per
100 000 males and 43 cancers per 100 000
females) (5). This should have substan-
tially reduced any potential ascertainment
bias in our Swiss population.
This line of reasoning is supported
also by the appreciably stronger excess
risk in our dataset (overall standardized
incidence ratio [SIR] after cervical,
vaginal, and vulvar cancers 4 2.1; 95%
confidence interval 4 1.6–2.7) com-
pared with an SIR of 1.3 (685 observed
versus 519 expected cases) in the Dan-
ish dataset. This excess risk of more
than twofold can hardly be explained
only by surveillance or ascertainment
bias. Further support for this view
comes from Table 1, which gives ex-
pected and observed numbers of all neo-
plasms and of nonmelanomatous skin
neoplasms during the period from 1974
through 1994 [thus updating a previous
report (6)] after colorectal, breast, and
endometrial cancers, i.e., the three neo-
plasms unlikely to be related to human
papillomavirus infection selected by
Frisch and Hjalgrim. The SIRs for none
of these neoplasms were above unity or
materially different between nonmela-
nomatous skin neoplasms and other can-
cers. Thus, in the Vaud population, in-
cidence of nonmelanomatous skin
cancer is elevated after human papillo-
mavirus-related neoplasms but not after
other selected cancers. Likewise, in the
Swedish record-linkage cohort study
(7), the incidence of cervical, vulvar,
and vaginal cancers was significantly el-
evated in patients with squamous cell
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Table 1. Observed and expected cases of cancer and standardized incidence ratios (SIRs), with
corresponding 95% confidence intervals (CIs), of subsequent cancers (overall) and nonmelanomatous
skin cancers among women with colorectal cancer, breast cancer, and cancer of the uterine corpus in
Vaud, Switzerland, during the period from 1974 through 1994
Site of
primary tumor













Colorectum 142 155.5 0.9 (0.8–1.1) 32 41.4 0.8 (0.5–1.1)
Breast 479 405.7 1.2 (1.1–1.3) 122 104.7 1.2 (1.0–1.4)
Uterine corpus 94 110.6 0.9 (0.7–1.0) 26 28.5 0.9 (0.6–1.3)
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